Raytheon awarded $71 million in Navy contracts for missile systems
John Fesko, President and Chief Business Officer at Natera, Inc. (NASDAQ:NTRA), sold 1,710 shares of common stock on July 28, 2025, at a price of $139.8083, for a total value of $239,072. The transaction occurred in a $19.2 billion market cap company that, according to InvestingPro analysis, is currently trading above its Fair Value.
Following the transaction, Fesko directly owns 151,750 shares of Natera.
The sale was executed to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) under a pre-arranged 10b5-1 trading plan.
In other recent news, Natera has reported a series of significant developments. The company showcased strong performance in the first quarter of 2025, prompting RBC Capital Markets to maintain their Outperform rating and a price target of $251. This confidence is supported by Natera’s accelerated revenue growth and increased financial guidance. Additionally, Medicare has expanded its coverage for Natera’s Signatera MRD assay to include a broader range of cancers, following a study presented at the American Society of Clinical Oncology Annual Meeting. This expansion is expected to enhance the company’s market reach.
Analysts at TD Cowen have also raised their price target for Natera to $200, citing a 13% sales increase, driven by a 5% rise in core sales and other favorable factors. The company’s Signatera product has shown remarkable growth, with clinical volumes rising to approximately 17,000 in the first quarter, a 52% year-over-year increase. Evercore ISI initiated coverage with an Outperform rating and a $170 price target, suggesting potential upside. Meanwhile, Leerink Partners reiterated their Outperform rating, maintaining a $220 price target, following Medicare’s coverage decision for Natera’s WGS Signatera assay. These developments reflect a positive outlook from multiple analyst firms on Natera’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.